Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Nature Reviews Cancer is Scopus-indexed (Q1, CiteScore 96.2), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Nature Research.
Checked against the index lists dated .
ISSN 1474-175XVerify ISSN ↗1474-1768Verify ISSN ↗
Publisher: Nature Research
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Cancer Research | 1 / 233 | 99th | Q1 |
| Oncology | 3 / 428 | 99th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2001–present, best quartile Q1, CiteScore 96.2.
Nature Reviews Cancer is Q1 in Cancer Research (rank 1 of 233) and Q1 in Oncology (rank 3 of 428), by CiteScore 2025.
Nature Reviews Cancer is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 96.2, which places it in quartile Q1 at the 99th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 22.814, quartile Q1, with an H-index of 548.
Nature Reviews Cancer is published by Nature Research. Its print ISSN is 1474-175X and its online ISSN is 1474-1768.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Nature Reviews Cancer has an h-index of 601 and a 2-year mean of 26.1 citations per paper (OpenAlex). Its Scopus CiteScore is 96.2, quartile Q1. On 2-year citations it ranks #5 of 229 Scopus journals in Cancer Research.
Nature Reviews Cancer published 115 papers in 2025; its busiest recent year was 2019 with 135. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 74 research articles (2025–2026), authors are most often from United States (46.1%), Mexico (11.5%) and China (8.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.4 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.